Actinogen Medical Ltd has released a press release.
First UK patient treated in ground-breaking clinical trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- June Quarterly Update
- First US Patients Treated in Landmark Alzheimers Trial
- First UK Site Goes Live in Global Alzheimers Clinical Trial
- First Patient Treated in Landmark Alzheimers Clinical Trial
- March Quarterly Update
Later from Actinogen Medical
- First Patient Completes Landmark Alzheimers Disease Trial
- Final Major Market Patent Granted for Xanamem
- Quarterly Update & Appendix 4C
- R&D Rebate Received Totalling $1.22 Million
- Placement Fully Funds Completion of XanADu Alzheimers Trial
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical